AI
BCRX icon

Atria Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Atria Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
12,046
+1,171
+11% +$10.6K ﹤0.01% 2084
2026
Q1 		$104K Sell
10,875
-3,217
-23% -$25K ﹤0.01% 2004
2025
Q4 		$110K Buy
14,092
+1,863
+15% +$13.5K ﹤0.01% 1999
2025
Q3 		$92.8K Buy
+12,229
New +$102K ﹤0.01% 1995

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Atria Investments's BCRX Position: Q2 2026 in Review

Atria Investments increased its BioCryst Pharmaceuticals (BCRX) stake by 11% in Q2 2026, buying an estimated $10.6K and bringing the position to 12,046 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Atria Investments first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Atria Investments held 12,046 shares of BioCryst Pharmaceuticals worth $120K as of Q2 2026.
  • Atria Investments bought 1,171 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $10.6K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #2084 holding.
  • Atria Investments first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.